Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients (HAITI)

G

Gruppo Oncologico del Nord-Ovest

Status and phase

Enrolling
Phase 2

Conditions

Colorectal Cancer Metastatic

Treatments

Procedure: 166Holmium TARE
Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Panitumumab
Drug: Bevacizumab
Drug: Cetuximab

Study type

Interventional

Funder types

Other

Identifiers

NCT06332079
HAITI 2023-505356-22-00

Details and patient eligibility

About

The aim of this study is to assess the efficacy of 166Ho-TARE followed by maintenance therapy with fluoropyrimidine and anti-EGFR or bevacizumab in liver-limited unresectable colorectal cancer patients, in terms of progression free rate 9- and 8-months for cohort A and B, respectively.

Full description

HAITI is a phase II, single-arm trial of 166Ho-TARE followed by maintenance therapy in liver-limited unresectable colorectal cancer patients, achieving partial response or stable disease according to RECIST 1.1 criteria after 6-12 cycles of induction first-line chemotherapy. Two cohorts of patients are included: left sided RAS/BRAF wild-type (cohort A) right-sided and/or RAS mutated (cohort B) Enrolled patients will be treated with different maintenance therapy according to study cohort (fluoropyrimidine + anti-EGFR or bevacizumab).

Enrollment

46 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Written informed consent to study procedures;
  • Age ≥18 years;
  • Histologically proven diagnosis of colorectal adenocarcinoma, with or without primary tumour in situ;
  • Liver-only disease at radiological exams involving less than 50% of liver volume;
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤2;
  • Patients with partial response or stable disease according to RECIST 1.1 criteria deemed unresectable after 6-12 cycles of induction first-line chemotherapy;
  • Life expectancy of at least 12 weeks;

Hematopoietic function: absolute neutrophil count ≥ 1,500/mm3; platelet count

≥100,000/mm3; haemoglobin level ≥ 9 g/dL;

Liver function: total bilirubin ≤ 1.5 times upper limit of normal (ULN); alkaline phosphatase

≤ 5 times ULN; AST ≤ 5 times ULN;

  • Renal function: creatinine clearance > 50 mL/min or serum creatinine 1.5 x UNL; no renal disease that would preclude study treatment or follow-up;
  • Women of childbearing potential must have a negative blood pregnancy test at the screening visit. For this trial, women of childbearing potential are defined as all women after puberty, unless they are postmenopausal for at least 12 months, are surgically sterile, or are sexually inactive. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient;
  • Subjects and their partners must be willing to avoid pregnancy during the trial. Male subjects with female partners of childbearing potential and female subjects of childbearing potential must, therefore, be willing to use adequate contraception as outlined in Section 7.5 - Contraception, starting during study screening visit throughout the study period up to 180 days after the last dose of chemotherapy Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject;
  • Will and ability to comply with the protocol

Inclusion criteria for Cohort A:

  • RAS/BRAF wild-type and left sided primary tumor

First-line induction chemotherapy regimen permitted up to 6-12 cycles with:

FOLFOX or FOLFIRI + anti-EGFR (cetuximab or panitumumab). Patients who interrupted anti-EGFR target therapy during induction phase due to toxicity or other reasons, candidate to maintenance with fluoropyridine alone therapy can be enrolled.

Inclusion criteria for Cohort B:

  • RAS mutated and/or right-sided primary tumor

First-line induction chemotherapy regimen admitted up to 6-12 cycles with:

FOLFOX/FOLFIRI/XELOX + bevacizumab or FOLFOXIRI + bevacizumab. Patients who interrupted bevacizumab during induction phase due to toxicity or other reasons, candidate to maintenance with fluoropyridine alone therapy can be enrolled.

Exclusion criteria

  • Patients with radiological evidence of extra liver distant metastases.
  • Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumour involvement or thrombosis, or any other contraindications to radioembolization treatment;
  • Previous radiotherapy delivered to the liver;
  • Patients with BRAF mutated and/or MSI-high tumours;
  • Previous history of malignancy within the last 5 years will be excluded with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ;
  • Treatment with any investigational drug within 30 days prior to enrolment or 2 investigational agent half-lives (whichever is longer);
  • Active uncontrolled infections or other clinically relevant concomitant illness contraindicating study procedures and treatment administration Clinically significant (e.g. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), serious cardiac arrhythmia requiring medication
  • Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study and until 180 days after the last trial treatment;
  • History of a previous allergic reaction to contrast media that would preclude safe angiography of the hepatic arteries, in the opinion of the treating Interventional Radiologist;
  • Known hypersensitivity to fluoropyrimidine, anti-VEGF or anti-EGFR MoAb.
  • Psychiatric or addictive disorders, or other conditions that, in the opinion of the investigator, would preclude study participation;
  • Withdrawal of the consent to take part to the study

Trial design

46 participants in 1 patient group

COHORT A/B
Experimental group
Description:
Eligible patients will receive Scout dose procedure. After 1-2 weeks, patients eligible for radioembolization will receive 166Ho-TARE and at least after 3 weeks, maintenance treatment with fluoropyrimidine plus target agents (anti-EGFR or bevacizumab) according to the respective study cohort. Maintenance treatment: Cohort A: CETUXIMAB iv day1, over 1 hours, 500 mg/sqm or PANITUMUMAB iv over 1 hours, 6 mg/kg, every 14 days LED 200 mg/sqm iv over 1 hour, day 1 5-FLUOROURACIL ic 48 h, starting on day 1 every 14 days; 2400 mg/sqm and 400 mg/sqm bolus if FOLFOX/FOLFIRI in the induction treatment Cohort B: BEVACIZUMAB 5 mg/kg iv biweekly day1, over 30 minutes LED 200 mg/sqm iv over 1 hour, day 1 5-FLUOROURACIL ic 48 h, starting on day 1 every 14 days; 2400 mg/sqm and 400 mg/sqm bolus if FOLFOX/FOLFIRI in the induction treatment CAPECITABINE, 1000 mg/sqm orally twice daily, day 1-14, plus bevacizumab 7,5 mg/kg iv every 21 days is allowed.
Treatment:
Drug: Cetuximab
Drug: Bevacizumab
Drug: 5-Fluorouracil
Drug: Panitumumab
Drug: Capecitabine
Procedure: 166Holmium TARE

Trial contacts and locations

0

Loading...

Central trial contact

Gianluca Masi, MD; Laura Delliponti

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems